CLINICAL TRIALS PROFILE FOR TIMOLOL MALEATE

All Clinical Trials for TIMOLOL MALEATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004641 ↗	Prevention of Esophageal Varices by Beta-Adrenergic Blockers	Completed	Yale University	Phase 3	1993-08-01	The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease. Cirrhosis causes an increased resistance of blood flowing through the liver. This leads to an increased pressure in the portal vein (the vein that takes blood to your liver). High portal pressure is responsible for the appearance of complications of chronic liver disease such as varices and variceal bleeding (bleeding from veins in your esophagus). Timolol belongs to a group of medications called beta-blockers. Beta-blockers decrease high portal pressure and previous studies have shown that beta-blocker pills are useful in preventing bleeding from varices in patients who already have varices. A more desirable effect would be if these pills could prevent not only bleeding from varices but the appearance of varices (and therefore of bleeding).
NCT00004641 ↗	Prevention of Esophageal Varices by Beta-Adrenergic Blockers	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3	1993-08-01	The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease. Cirrhosis causes an increased resistance of blood flowing through the liver. This leads to an increased pressure in the portal vein (the vein that takes blood to your liver). High portal pressure is responsible for the appearance of complications of chronic liver disease such as varices and variceal bleeding (bleeding from veins in your esophagus). Timolol belongs to a group of medications called beta-blockers. Beta-blockers decrease high portal pressure and previous studies have shown that beta-blocker pills are useful in preventing bleeding from varices in patients who already have varices. A more desirable effect would be if these pills could prevent not only bleeding from varices but the appearance of varices (and therefore of bleeding).
NCT00006398 ↗	Prevention of Esophageal Varices by Beta-Adrenergic Blockers	Completed	Yale University	Phase 3	1993-08-01	The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease. Cirrhosis causes an increased resistance of blood flowing through the liver. This leads to an increased pressure in the portal vein (the vein that takes blood to your liver). High portal pressure is responsible for the appearance of complications of chronic liver disease such as varices and variceal bleeding (bleeding from veins in your esophagus). Timolol belongs to a group of medications called beta-blockers. Beta-blockers decrease high portal pressure and previous studies have shown that beta-blocker pills are useful in preventing bleeding from varices in patients who already have varices. A more desirable effect would be if these pills could prevent not only bleeding from varices but the appearance of varices (and therefore of bleeding).
NCT00006398 ↗	Prevention of Esophageal Varices by Beta-Adrenergic Blockers	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3	1993-08-01	The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease. Cirrhosis causes an increased resistance of blood flowing through the liver. This leads to an increased pressure in the portal vein (the vein that takes blood to your liver). High portal pressure is responsible for the appearance of complications of chronic liver disease such as varices and variceal bleeding (bleeding from veins in your esophagus). Timolol belongs to a group of medications called beta-blockers. Beta-blockers decrease high portal pressure and previous studies have shown that beta-blocker pills are useful in preventing bleeding from varices in patients who already have varices. A more desirable effect would be if these pills could prevent not only bleeding from varices but the appearance of varices (and therefore of bleeding).

Clinical Trial Conditions for TIMOLOL MALEATE

Condition Name

Condition Name for TIMOLOL MALEATE
Intervention	Trials
Ocular Hypertension	38
Glaucoma	19
Open-angle Glaucoma	14
Primary Open Angle Glaucoma	5

Condition MeSH

Condition MeSH for TIMOLOL MALEATE
Intervention	Trials
Glaucoma	49
Ocular Hypertension	43
Hypertension	36
Glaucoma, Open-Angle	36

Clinical Trial Locations for TIMOLOL MALEATE

Trials by Country

Trials by Country for TIMOLOL MALEATE
Location	Trials
United States	123
Spain	8
Germany	4
United Kingdom	4
Canada	4

Trials by US State

Trials by US State for TIMOLOL MALEATE
Location	Trials
California	12
New York	8
Georgia	8
Massachusetts	8
New Jersey	6

Clinical Trial Progress for TIMOLOL MALEATE

Clinical Trial Phase

Clinical Trial Phase for TIMOLOL MALEATE
Clinical Trial Phase	Trials
Phase 4	20
Phase 3	17
Phase 2	16

Clinical Trial Status

Clinical Trial Status for TIMOLOL MALEATE
Clinical Trial Phase	Trials
Completed	47
Recruiting	9
Active, not recruiting	5

Clinical Trial Sponsors for TIMOLOL MALEATE

Sponsor Name

Sponsor Name for TIMOLOL MALEATE
Sponsor	Trials
Alcon Research	8
Allergan	5
Aerie Pharmaceuticals	5

Sponsor Type

Sponsor Type for TIMOLOL MALEATE
Sponsor	Trials
Industry	50
Other	27
NIH	3